Greef Roderick De Sells 31,165 Shares of BioLife Solutions (NASDAQ:BLFS) Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) CEO Greef Roderick De sold 31,165 shares of BioLife Solutions stock in a transaction that occurred on Thursday, November 13th. The shares were sold at an average price of $25.33, for a total transaction of $789,409.45. Following the transaction, the chief executive officer directly owned 389,998 shares in the company, valued at approximately $9,878,649.34. This trade represents a 7.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Greef Roderick De also recently made the following trade(s):

• On Wednesday, November 12th, Greef Roderick De sold 33,418 shares of BioLife Solutions stock. The shares were sold at an average price of $25.88, for a total transaction of $864,857.84.
• On Tuesday, November 11th, Greef Roderick De sold 35,417 shares of BioLife Solutions stock. The stock was sold at an average price of $26.15, for a total value of $926,154.55.
• On Wednesday, October 22nd, Greef Roderick De sold 37,795 shares of BioLife Solutions stock. The shares were sold at an average price of $27.30, for a total value of $1,031,803.50.

BioLife Solutions Price Performance

BioLife Solutions stock opened at $24.07 on Friday. BioLife Solutions, Inc. has a 12-month low of $19.10 and a 12-month high of $29.62. The company has a market capitalization of $1.16 billion, a price-to-earnings ratio of -200.57 and a beta of 1.97. The firm’s fifty day moving average price is $26.55 and its 200 day moving average price is $24.12.

Analysts Set New Price Targets

Several research firms recently commented on BLFS. Stephens started coverage on BioLife Solutions in a research note on Tuesday, July 22nd. They issued an “overweight” rating and a $30.00 price target on the stock. HC Wainwright restated a “buy” rating and set a $32.00 price objective (up previously from $30.00) on shares of BioLife Solutions in a research note on Friday, August 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioLife Solutions in a research report on Wednesday, October 8th. Finally, Zacks Research raised BioLife Solutions from a “hold” rating to a “strong-buy” rating in a research report on Friday, November 7th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, BioLife Solutions currently has an average rating of “Moderate Buy” and a consensus target price of $31.20.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Hantz Financial Services Inc. grew its stake in BioLife Solutions by 54.1% during the 3rd quarter. Hantz Financial Services Inc. now owns 1,877 shares of the medical equipment provider’s stock worth $48,000 after buying an additional 659 shares during the last quarter. State of Wyoming grew its position in shares of BioLife Solutions by 353.1% during the first quarter. State of Wyoming now owns 1,912 shares of the medical equipment provider’s stock worth $44,000 after acquiring an additional 1,490 shares during the last quarter. US Bancorp DE grew its position in shares of BioLife Solutions by 243.7% during the first quarter. US Bancorp DE now owns 2,155 shares of the medical equipment provider’s stock worth $49,000 after acquiring an additional 1,528 shares during the last quarter. Ameritas Investment Partners Inc. increased its holdings in shares of BioLife Solutions by 12.8% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,873 shares of the medical equipment provider’s stock worth $83,000 after acquiring an additional 441 shares during the period. Finally, PNC Financial Services Group Inc. lifted its position in BioLife Solutions by 82.0% in the 3rd quarter. PNC Financial Services Group Inc. now owns 4,425 shares of the medical equipment provider’s stock valued at $113,000 after purchasing an additional 1,994 shares during the last quarter. Institutional investors and hedge funds own 93.24% of the company’s stock.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.